---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-142578"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2021-11-22T23:59:59+00:00"
generated_at: "2026-06-28T06:07:46.764308+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience reports record FY2021 revenue $132.3M (+47% YoY), guides FY2022 rev $183M-$193M

## Summary
- FY2021 revenue $132.3M, up 47% from $90.1M; net loss $152.1M vs $139.9M.
- Q4 revenue $38.0M (+17% YoY); net loss $41.2M ($0.84/share) vs $24.3M ($0.54/share).
- FY2022 revenue guidance $183M-$193M, representing ~42% growth at midpoint.
- Cash and investments $477.9M at Sept 30, 2021.
- Announced acquisition of Abveris to add in vivo antibody discovery capabilities.

## SEC filing metadata
- accession: 0001104659-21-142578
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2021-11-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000110465921142578/0001104659-21-142578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000110465921142578/tm2133571d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-142578
- JSON: https://secwatch.observer/filing/0001104659-21-142578.json
- Plain text: https://secwatch.observer/filing/0001104659-21-142578.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.